ProfileGDS5678 / 1424933_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 53% 53% 52% 53% 53% 52% 53% 53% 52% 54% 54% 53% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3507453
GSM967853U87-EV human glioblastoma xenograft - Control 23.3086653
GSM967854U87-EV human glioblastoma xenograft - Control 33.3139353
GSM967855U87-EV human glioblastoma xenograft - Control 43.2152352
GSM967856U87-EV human glioblastoma xenograft - Control 53.2474653
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3961953
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3435652
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2899153
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2945453
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2608252
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3108154
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3064254
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3010953
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3018953